Optibrium Launches Sentira: New Software for Compound Data Visualisation
Optibrium™, a developer of software for drug discovery, today announced the launch of Sentira, a new desktop application that provides dynamic data visualisation and analysis of compound data. Applicable across all fields of chemistry, Sentira enables users to quickly find patterns in compound data, visualise structure-activity relationships (SAR) and elegantly present and report findings. Researchers can intuitively review and interpret compound data sets from large screening libraries to individual chemical series.
Sentira provides a comprehensive range of plots, all with extensive and fully customisable features. Multiple plots can be created side-by-side, all dynamically linked to each other and the underlying data set, enabling quick identification of important relationships between compound properties. Flexible tools for SAR and matched pair analysis, coupled with a link to the underlying compound structures, affords insightful and intelligent compound data analysis.
Sentira’s simple design and user-friendly environment provides data management tools to perform calculations, merge, sort, filter and tag data sets, and import and export industry standard file formats on Mac or PC. Sentira also makes it easy to professionally present the results of analyses in presentations and reports.
Available for download from www.sentira-software.com, users can immediately get started with a free 30-day trial. Following this, flexible and cost-effective Sentira licensing options are available, including monthly, annual and perpetual plans.
Dr Matthew Segall, Optibrium’s CEO, commented: “We recognised the need for a user-friendly, yet powerful, compound data visualisation application at a reasonable price. By leveraging the development that we had already undertaken in StarDrop, we are pleased to be able to offer such a solution as part of our expanded range of software products.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance